Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,858 | -18,851 | -15,274 | -14,495 | -9,458 |
| Depreciation Amortization | 3 | 4 | 12 | 13 | 11 |
| Accounts payable and accrued liabilities | -3,634 | 1,322 | 2,304 | 1,035 | 657 |
| Other Working Capital | -3,694 | 3,699 | 3,164 | -780 | 834 |
| Other Operating Activity | 5,069 | -314 | -764 | 689 | 638 |
| Operating Cash Flow | $-17,113 | $-14,140 | $-10,558 | $-13,538 | $-7,318 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4 | -4 | -4 | -6 | -18 |
| Investing Cash Flow | $-4 | $-4 | $-4 | $-6 | $-18 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 23,398 | 5,279 | 16,041 | 4,987 | 14,222 |
| Other Financing Activity | -368 | -642 | -428 | -478 | -88 |
| Financing Cash Flow | $23,030 | $4,637 | $15,613 | $4,509 | $14,134 |
| Beginning Cash Position | 549 | 10,055 | 5,005 | 14,040 | 7,241 |
| End Cash Position | 6,461 | 549 | 10,055 | 5,005 | 14,040 |
| Net Cash Flow | $5,913 | $-9,507 | $5,051 | $-9,035 | $6,798 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,113 | -14,140 | -10,558 | -13,538 | -7,318 |
| Capital Expenditure | -4 | -4 | -4 | -6 | -18 |
| Free Cash Flow | -17,118 | -14,144 | -10,562 | -13,544 | -7,336 |